475 related articles for article (PubMed ID: 37240281)
21. Regulatory role of PI 3-kinase on expression of Cdk4 and p27, nuclear localization of Cdk4, and phosphorylation of p27 in corneal endothelial cells.
Lee HT; Kay EP
Invest Ophthalmol Vis Sci; 2003 Apr; 44(4):1521-8. PubMed ID: 12657588
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of the melanoma cell cycle and regulation at the G1/S transition by 12-O-tetradecanoylphorbol-13-acetate (TPA) by modulation of CDK2 activity.
Coppock DL; Buffolino P; Kopman C; Nathanson L
Exp Cell Res; 1995 Nov; 221(1):92-102. PubMed ID: 7589260
[TBL] [Abstract][Full Text] [Related]
23. c-Myc regulates cyclin D-Cdk4 and -Cdk6 activity but affects cell cycle progression at multiple independent points.
Mateyak MK; Obaya AJ; Sedivy JM
Mol Cell Biol; 1999 Jul; 19(7):4672-83. PubMed ID: 10373516
[TBL] [Abstract][Full Text] [Related]
24. Cyclic AMP-dependent phosphorylation of cyclin D3-bound CDK4 determines the passage through the cell cycle restriction point in thyroid epithelial cells.
Paternot S; Coulonval K; Dumont JE; Roger PP
J Biol Chem; 2003 Jul; 278(29):26533-40. PubMed ID: 12730225
[TBL] [Abstract][Full Text] [Related]
25. Cyclin-dependent kinases in cancer: Role, regulation, and therapeutic targeting.
Gupta A; Dagar G; Chauhan R; Sadida HQ; Almarzooqi SK; Hashem S; Uddin S; Macha MA; Akil ASA; Pandita TK; Bhat AA; Singh M
Adv Protein Chem Struct Biol; 2023; 135():21-55. PubMed ID: 37061333
[TBL] [Abstract][Full Text] [Related]
26. Loss of p27Kip1 from cyclin E/cyclin-dependent kinase (CDK) 2 but not from cyclin D1/CDK4 complexes in cells transformed by polyamine biosynthetic enzymes.
Ravanko K; Järvinen K; Paasinen-Sohns A; Hölttä E
Cancer Res; 2000 Sep; 60(18):5244-53. PubMed ID: 11016654
[TBL] [Abstract][Full Text] [Related]
27. Dual action of the inhibitors of cyclin-dependent kinases: targeting of the cell-cycle progression and activation of wild-type p53 protein.
Wesierska-Gadek J; Schmid G
Expert Opin Investig Drugs; 2006 Jan; 15(1):23-38. PubMed ID: 16370931
[TBL] [Abstract][Full Text] [Related]
28. Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.
Spring LM; Zangardi ML; Moy B; Bardia A
Oncologist; 2017 Sep; 22(9):1039-1048. PubMed ID: 28706010
[TBL] [Abstract][Full Text] [Related]
29. Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells.
Kang J; Sergio CM; Sutherland RL; Musgrove EA
BMC Cancer; 2014 Jan; 14():32. PubMed ID: 24444383
[TBL] [Abstract][Full Text] [Related]
30. [Molecular mechanisms controlling the cell cycle: fundamental aspects and implications for oncology].
Viallard JF; Lacombe F; Belloc F; Pellegrin JL; Reiffers J
Cancer Radiother; 2001 Apr; 5(2):109-29. PubMed ID: 11355576
[TBL] [Abstract][Full Text] [Related]
31. Naturally Sourced CDK Inhibitors and Current Trends in Structure-Based Synthetic Anticancer Drug Design by Crystallography.
Nandi S; Dey R; Dey S; Samadder A; Saxena AK
Anticancer Agents Med Chem; 2022; 22(3):485-498. PubMed ID: 34503422
[TBL] [Abstract][Full Text] [Related]
32. Silymarin and silibinin cause G1 and G2-M cell cycle arrest via distinct circuitries in human prostate cancer PC3 cells: a comparison of flavanone silibinin with flavanolignan mixture silymarin.
Deep G; Singh RP; Agarwal C; Kroll DJ; Agarwal R
Oncogene; 2006 Feb; 25(7):1053-69. PubMed ID: 16205633
[TBL] [Abstract][Full Text] [Related]
33. Induction of p18INK4c and its predominant association with CDK4 and CDK6 during myogenic differentiation.
Franklin DS; Xiong Y
Mol Biol Cell; 1996 Oct; 7(10):1587-99. PubMed ID: 8898364
[TBL] [Abstract][Full Text] [Related]
34. Transforming growth factor beta(1) selectively inhibits the cyclic AMP-dependent proliferation of primary thyroid epithelial cells by preventing the association of cyclin D3-cdk4 with nuclear p27(kip1).
Depoortere F; Pirson I; Bartek J; Dumont JE; Roger PP
Mol Biol Cell; 2000 Mar; 11(3):1061-76. PubMed ID: 10712520
[TBL] [Abstract][Full Text] [Related]
35. Antiestrogen inhibition of cell cycle progression in breast cancer cells in associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation.
Watts CK; Brady A; Sarcevic B; deFazio A; Musgrove EA; Sutherland RL
Mol Endocrinol; 1995 Dec; 9(12):1804-13. PubMed ID: 8614416
[TBL] [Abstract][Full Text] [Related]
36. The cyclin D3-CDK4-p27kip1 holoenzyme in thyroid epithelial cells: activation by TSH, inhibition by TGFbeta, and phosphorylations of its subunits demonstrated by two-dimensional gel electrophoresis.
Coulonval K; Bockstaele L; Paternot S; Dumont JE; Roger PP
Exp Cell Res; 2003 Nov; 291(1):135-49. PubMed ID: 14597415
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of cyclin-dependent kinases 2 and 4 activities as well as induction of Cdk inhibitors p21 and p27 during growth arrest of human breast carcinoma cells by (-)-epigallocatechin-3-gallate.
Liang YC; Lin-Shiau SY; Chen CF; Lin JK
J Cell Biochem; 1999 Oct; 75(1):1-12. PubMed ID: 10462699
[TBL] [Abstract][Full Text] [Related]
38. CDK2 is a target for retinoic acid-mediated growth inhibition in MCF-7 human breast cancer cells.
Teixeira C; Pratt MA
Mol Endocrinol; 1997 Aug; 11(9):1191-202. PubMed ID: 9259311
[TBL] [Abstract][Full Text] [Related]
39. Cyclin-dependent kinases regulate the antiproliferative function of Smads.
Matsuura I; Denissova NG; Wang G; He D; Long J; Liu F
Nature; 2004 Jul; 430(6996):226-31. PubMed ID: 15241418
[TBL] [Abstract][Full Text] [Related]
40. Cyclin-Dependent Kinase 4 and 6 Inhibitors in Cell Cycle Dysregulation for Breast Cancer Treatment.
Susanti NMP; Tjahjono DH
Molecules; 2021 Jul; 26(15):. PubMed ID: 34361615
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]